Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2006 | 1 | 4 | 348-355

Article title

Hypolipidemic effect of a pro-drug containing nicotinic acid in rats


Title variants

Languages of publication



We studied the release of nicotinic acid from a macromolecular pro-drug containing niacin bound to a polymeric support of dextran. Using a modified High-performance Liquid Chromatography (HPLC) method to provide an improved separation between nicotinic acid and its metabolites, we compared the plasma levels of nicotinic acid 24 h after administration of the pro-drug or a similar dose of unbound nicotinic acid to rats. Nicotinic acid exerts a number of pharmacological activities among which is the hypolipidemic effect. To determine the hypolipidemic effect of the pro-drug, we measured the triglyceride levels and examined the correlation with the plasma levels of nicotinic acid.Starting 6 h after administration of the pro-drug, the plasma levels of nicotinic acid were high enough to cause a decrease in the triglyceride level. These results suggest that nicotinic acid was gradually released from the polymeric support, leading to the sustained presence of the active substance and, therefore, a reduction in the level of triglycerides.










Physical description


1 - 12 - 2006
11 - 11 - 2006


  • Department of Biochemistry, University of Medicine and Pharmacy, Iasi, Romania
  • Department of Pharmacology, University of Medicine and Pharmacy, Iasi, Romania
  • Department of Biochemistry, University of Medicine and Pharmacy, Iasi, Romania
  • Institute of Public Health “M. Ciuca”, Iasi, Romania
  • Institute of Macromolecular Chemistry “P. Poni”, Iasi, Romania
  • Department of Biochemistry, University of Medicine and Pharmacy, Iasi, Romania


  • [1] L.A. Carlson: “Nicotinic acid and other therapies for raising high-density lipoprotein Nicotinic acid”, Curr. Opin. Cardiol., Vol. 21, (2006), pp. 336–344. http://dx.doi.org/10.1097/01.hco.0000231404.76930.e9[Crossref]
  • [2] Y. Lomnicky, M. Friedman, M.H. Luria, I. Raz and A. Hoffman: “The effect of the mode of administration on the hypolipidaemic activity of niacin: continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats”, J. Pharm. Pharmacol., Vol. 50, (1988), pp. 1233–1239.
  • [3] The Pharmaceutical Codex, 11th ed., Pharmaceutical Press, London, 1979.
  • [4] N. Hengen, V. Seiberth and M. Hengen: “High-performance liquid-chromatoghaphic determination of free nicotinic acid and its metabolite, nicotinuric acid, in plasma and urine”, Clin. Chem., Vol. 24, (1978), pp. 1740–1743. [PubMed]
  • [5] J. Pan, J.T. Van, E. Chan, R.L. Kesala, M. Lin and M.A. Charles: “Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes”, Metabolism, Vol. 51, (2002), pp. 1120–1127. http://dx.doi.org/10.1053/meta.2002.34701[Crossref]
  • [6] A. Vogt, U. Kassner, U. Hostalek, E. Steinhagen-Thiessen; NAUTILUS Study Group: “Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study”, Curr. Med. Res. Opin., Vol. 22, (2006), pp. 417–425. http://dx.doi.org/10.1185/030079906X89766[Crossref]
  • [7] G. Mocanu, A. Airinei, and A. Carpov: “Macromolecular drug-conjugates. IV Nicotinic acid and nicotinamide/dextran derivatives”, STP Pharma. Sci., Vol. 4, (1994), pp. 287–291.
  • [8] A.M. Gotto Jr: “Triglyceride as a risk factor for coronary artery disease”, Am. J. Cardiol., Vol. 82, (1998), pp. 22Q–25Q. [Crossref][PubMed]
  • [9] J. McKenney:” New perspectives on the use of niacin in the treatment of lipid disorders”, Arch. Intern. Med., Vol. 164, (2004), pp. 697–705. http://dx.doi.org/10.1001/archinte.164.7.697[Crossref]
  • [10] H.N. Ginsberg: “Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease”, Curr. Cardiol. Rep., 1999, Vol. 1, (1999), pp. 233–237. [PubMed][Crossref]
  • [11] I. Gouni-Berthold and W. Krone: “Hypertriglyceridemia-why, when and how should it be treated?”, Z. Kardiol., Vol. 94, (2005), pp. 731–739. http://dx.doi.org/10.1007/s00392-005-0295-1[Crossref]
  • [12] K. Takikawa, K. Miyazaki and T. Arita: “High-performance liquid chromatographic determination of nicotinic acid and its metabolites, nicotinuric acid and nicotinamide, in plasma”, J. Chromatogr., Vol. 233, (1982), pp. 343–348.
  • [13] L. Saubetin, G. Galli, L. Puglisi, M.G. Ciapponi and R. Paoletti: “Analysis of free nicotinic acid released by a polymeric preparation using a mass fragmentographic technique”, Pharmacol. Res. Commun., Vol. 2, (1981), pp. 141–149.
  • [14] R. Gugler: “Clinical pharmacokinetics of hypolipidaemic drugs”, Clin. Pharmacokinet., Vol. 3, (1978), pp. 425–439. [PubMed][Crossref]
  • [15] K. Shibata: “Simultaneous Measurement of nicotinic acid and its major metabolite in blood and urine by a reversed-phase high-performance liquid chromatography”, Agric. Biol. Chem., Vol. 52, (1988), pp. 2973–2976. [Crossref]
  • [16] M. Iwaki, T. Ogiso, H. Hayashi, E.T. Lin and L.Z. Benet: “Simultaneous measurement of nicotinic acid and its major metabolite, nicotinuric acid in urine using high-performance liquid chromatography; application of solid-liquid extraction”, J. Chromatogr., Vol. 661, (1994), pp. 154–158.

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.